Anne Whitaker, CEO, Aerami Therapeutics talks about imatinib their inhaled treatment for the rare disease pulmonary arterial hypertension which could potentially be the first therapy on the market to actually reverse the disease. First approved as a cancer therapy, imatinib stops the progression of the stiffening and thickening of the blood vessels in the lungs and is delivered using a breath-activated, Bluetooth enabled, hand-held nebulizer device delivering the drug centrally in the lung and in the peripheral area.
@aeramiTx #inhaledtherapies #RespiratoryDiseases #PulmonaryArterialHypertension #PAH #imatinib
Aerami.com
Download the transcript here
Empowered Patient Podcast